Solid Biosciences Inc.
NASDAQ:SLDBBiotechnology
Healthcare
$6.23 +3.63%
+$0.27 today
- Market cap
- $695.33M
- Beta
- 2.43
- P/E (TTM)
- -4.3
- EPS (TTM)
- -$1.75
52W Low $3.79High $8.87
Volume 1.13M
Average 1.39M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$156.29M
FY 2025 · Annual
Investing Cash Flow
-$58.45M
FY 2025 · Annual
Financing Cash Flow
$194.45M
FY 2025 · Annual
+58.8% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (72.19M) | (85.98M) | (96.02M) | (124.7M) | (174.33M) |
| Depreciation & Amortization | 2.96M | 2.41M | 2.58M | 2.46M | (1.87M) |
| Deferred Income Tax | 1.21M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 13.37M | 7.54M | 7.63M | 10.52M | 16.91M |
| Change in Working Capital | (23.04M) | (3.69M) | (6.34M) | 2.85M | (6.82M) |
| Accounts Receivables | (110K) | 110K | 0 | 0 | 0 |
| Inventory | (11.5M) | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.21M | (5.25M) | (764K) | 2.21M | (1.09M) |
| Other Working Capital | (12.64M) | 1.45M | (5.57M) | 645K | (5.73M) |
| Other Non-Cash Items | (81K) | (18.25M) | (2.03M) | 8.86M | 9.82M |
| Operating Cash Flow | (77.76M) | (97.98M) | (94.18M) | (100.01M) | (156.29M) |
| Capital Expenditures | (1.28M) | (3.02M) | (1.52M) | (654K) | (1.15M) |
| Acquisitions (Net) | 89.81M | 31.52M | 0 | 5K | 85K |
| Purchases of Investments | (141.25M) | (182.76M) | (117.43M) | (204.34M) | (235.89M) |
| Sales of Investments | 51.44M | 212.81M | 128.63M | 188.9M | 178.5M |
| Other Investing Activities | (89.81M) | 600K | 0 | 0 | 0 |
| Investing Cash Flow | (91.09M) | 59.16M | 9.69M | (16.09M) | (58.45M) |
| Debt Repayment | 0 | 2.08M | 0 | (473K) | (723K) |
| Common Stock Issued | 134.88M | 72.55M | 2.97M | 127.23M | 194.74M |
| Common Stock Repurchased | 0 | 0 | 0 | (5.11M) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 107K | 203K | 148K | 794K | 425K |
| Financing Cash Flow | 134.99M | 74.83M | 3.12M | 122.44M | 194.45M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (33.87M) | 36.01M | (81.37M) | 6.34M | (20.3M) |
| Free Cash Flow | (79.05M) | (100.99M) | (95.7M) | (100.67M) | (157.44M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$174.3M
+ D&A-$1.9M
+ Stock-Based Comp$16.9M
+ Deferred Tax$0
- Working Capital-$6.8M
+ Other Non-Cash$9.8M
= Operating Cash Flow-$156.3M
- Capex-$1.2M
= Free Cash Flow-$157.4M
Analysis
FY2025 free cash flow is -$157.4M. FCF conversion is 90.3% of net income. Operating cash flow was -$156.3M, with capex of -$1.2M. The largest bridge item is Stock-Based Comp at $16.9M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13D/A | SC 13D/A filing | Nov 6, 2026 | |
| 10-Q | Quarterly report | Nov 4, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 26, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 20, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 6, 2026 |
Does SLDB generate free cash flow?
Solid Biosciences Inc. (SLDB) generated -$157.44M of free cash flow in fiscal 2025.
How much operating cash flow does SLDB produce?
Operating cash flow was -$156.29M, before capital expenditures of $1.15M.
Continue the stock analysis
Jump to another research area for this company.